Immunodiagnostic Systems Holdings PLC

24 February 2017

Update on CEO Appointment

Immunodiagnostic Systems Holdings plc ("IDS"), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market today provides an update following the announcement on 19 January 2017 that Patricio Lacalle would be succeeded by Regis Duval as CEO.  

IDS is pleased to confirm that Regis will join on 1 March 2017.

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name and age: Regis Jacques Duval (aged 45)

Current Directorships and Partnerships

N/A

Previous Directorships and Partnerships in last five years:

Bio-Rad spol. s.r.o.

Bio-Rad Magyarország Kft.

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

For further information:

About Immunodiagnostic Systems Holdings PLC:

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.